For the Inventor, By the Inventor

Enter assignee name

Rahway, NJ, United States of America

Merck Sharp + Dohme Corp.

USPTO Granted Patents = 2,405

CIPO Patents = 121

EPO Patents = 1,348

Trademarks = 328

Forward Citations = 11,600

Loading Chart...

Loading Chart...

3,390 inventors (with patents filed for the assignee):

Scott D Kuduk (80 out of 118 patents)

Andrew William Stamford (74 out of 125 patents)

Jared N Cumming (69 out of 79 patents)

4. Leslie Joseph Street (68 out of 70 patents)

5. Amjad Ali (61 out of 65 patents)

6. Michael D Altman (56 out of 56 patents)

7. Raymond Baker (56 out of 63 patents)

8. Angus Murray MacLeod (53 out of 58 patents)

9. Christopher John Swain (53 out of 54 patents)

10. Joseph A Kozlowski (52 out of 104 patents)

11. Timothy Harrison (51 out of 73 patents)

12. Ian M Bell (49 out of 70 patents)

13. Jose Luis Castro Pineiro (48 out of 56 patents)

14. Janusz Jozef Kulagowski (47 out of 73 patents)

15. Tesfaye Biftu (45 out of 84 patents)

Core Competencies:

Adenosine Receptor Antagonists

Plasma Kallikrein Inhibitors

Antibacterial Agents

Natriuretic Peptide Receptor Agonists

PRMT5 Inhibitors

Diacylglyceride O-Acyltransferase Inhibitors

Cancer Therapeutics

Histone Deacetylase Inhibitors

Orexin Receptor Agonists

KRAS G12C Inhibitors

Anti-PD-1 Antibodies

Immunogenic SARS-CoV-2 Proteins

2,405 patents: Sort by Forward Citations

1. 12466831 - Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use (2025-11-11),

2. 12459933 - Compounds and methods of use thereof as antibacterial agents (2025-11-04),

3. 12459927 - Plasma kallikrein inhibitors (2025-11-04),

4. 12458633 - Treatment of migraine (2025-11-04),

5. 12458632 - Treatment of migraine (2025-11-04),

6. 12454525 - IL4I1 inhibitors and methods of use (2025-10-28),

7. 12448384 - Diacylglyceride O-acyltransferase 2 inhibitors (2025-10-21),

8. 12441792 - Antibodies specific for immunoglobulin-like transcript 3 (ILT3) and uses thereof (2025-10-14),

9. 12441730 - PRMT5 inhibitors (2025-10-14),

10. 12440496 - Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes (2025-10-14),

11. 12435133 - Antibodies specific for immunoglobulin-like transcript 3 (ILT3) and uses thereof (2025-10-07),

12. 12435077 - Oxazolidinone compound and methods of use thereof as an antibacterial agent (2025-10-07),

13. 12428411 - Preparation of oxindole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors (2025-09-30),

14. 12428397 - Factor XI activation inhibitors (2025-09-30),

15. 12427187 - Glucose-responsive insulin conjugates (2025-09-30),

Merck Sharp + Dohme Corp., a subsidiary of Merck & Co., Inc., is a global pharmaceutical company known for its innovative medicines, vaccines, and healthcare solutions. With a focus on research and development, Merck strives to improve the health and well-being of people worldwide. The company is committed to advancing medical science and addressing unmet medical needs.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

2,405 Patents

#2 in Rahway, NJ

#13 in New Jersey

#194 in US

#396 in the World

Rahway, NJ, United States of America

Merck Sharp + Dohme Corp.

Forward Citations = 11,600

3,390 inventors:

Scott D Kuduk (80 out of 118 patents)

Andrew William Stamford (74 out of 125 patents)

Jared N Cumming (69 out of 79 patents)

4. Leslie Joseph Street (68 out of 70 patents)

5. Amjad Ali (61 out of 65 patents)

Please report any incorrect information to support@idiyas.com

Loading…